Early Cancer Detection: Will New Screening Technology Disrupt Cancer Care?
The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.
You may also be interested in...
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
Deals give the company access to technologies to increase the accuracy of multi-cancer blood tests.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.